Access all of the content
It was a pleasure to be able to speak with John Stone (Massachusetts General Hospital, Boston, MA, USA) about the findings from his investigations into tocilizumab as a therapy for COVID-19 infection.
His presentation entitled ‘Tocilizumab for COVID-19 Infection: A Randomized, Double-Blind, Placebo-Controlled Trial’ (Abstract Number: L07) was presented at the ACR Convergence, 5-9 November.
- What is the rationale for the use of tocilizumab for COVID-19 infection? (0:16)
- What is the rationale for the use of tocilizumab for COVID-19 infection? (1:40)
- What might explain tocilizumab’s lack of efficacy in this treatment setting? (3:07)
- How do these findings compare with other studies of tocilizumab for COVID-19 infection? (4:32)
- Is tocilizumab likely to play any role in the treatment of COVID-19 outcomes? (5:20)
Disclosures: John H. Stone has received research funding from Roche, Principia, Viela Bio and Bristol Myers Squibb; and consulting fees from Roche, Principia, Viela Bio, Bristol Myers Squibb, Sanofi, Chemocentryx, Celgene, Abbvie, Chugai, Grunenthal, Glaxo Smith Kline, Infla Rx, Insmed, Regeneron, Roivant, Q32 bio, and SpruceBiosciences.
Support: Interview and filming supported by Touch Medical Media Ltd.
Filmed in coverage of virtual ACR Convergence 2020.
Share this Video
Related Videos In COVID-19
Patrick Durez, ACR 2022: Factors associated with disease flare following COVID vaccination in inflammatory rheumatic and musculoskeletal diseases
The EULAR Coronavirus Vaccine (COVAX) physician-reported registry registered patients with pre-existing rheumatic and musculoskeletal diseases, who have been vaccinated against COVID-19. touchIMMUNOLOGY were delighted to speak with Prof Patrick Durez (Cliniques Universitaires Saint-Luc – Université Catholique de Louvain (UCL), Brussels, Belgium) to discuss the aims, methodology and findings of this study looking at factors associated […]
Giovanni Marasco, UEG Week 2022: Findings from the GI-COVID-19 Study
The GI-COVID-19 study (ClinicalTrials.gov NCT04691895) was a prospective, multicenter, controlled study investigating the prevalence of gastrointestinal (GI) symptoms in hospitalized patients with COVID-19. We were delighted to talk with Dr. Giovanni Marasco (Sant’Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy) to discuss the aims, methodology and findings in terms of prevalence of GI symptoms in patients with COVID-19 […]
James Alexander, UEG Week 2022: Antibody and T-cell Response to the Third COVID-19 Vaccine Dose in Immunosuppressed Patients with Inflammatory Bowel Disease
The VIP study was a multicentre, prospective, case-control study, investigating whether immunosuppressive treatments reduced antibody and T-cell responses in patients with inflammatory bowel disease (IBD) after a third COVID-19 vaccine dose. In this touchIMMUNOLOGY interview, we speak with Dr. James Alexander (Imperial College London, London, UK) to discuss the aims, methodology and findings from the […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!